Belantamab Mafadotin in Treating Multiple Myeloma

Belantamab mafadotin is an immunoconjugate targeting B-cell maturation antigen, a pathway shown to be important for the growth and survival of myeloma cells. The drug is currently under investigation for the treatment of multiple myeloma, the second most common blood cancer. It was granted Breakthrough Therapy designation from the FDA in 2017 for this indication, and then priority review in…

Read the full article here